Baidu
map

Hepatology:鞘氨醇激酶1通过促进CCR2的表达来促进肝纤维化

2018-09-27 MedSci MedSci原创

在肝纤维化中,在激活KCs和HSCs中,SphK1具有独特的作用。从机制上说,在KCs中,SphK1减少 CCL2的分泌;在HSCs,SphK1通过下调 miR-19b-3p的表达,促进CCR2的表达。

研究背景:在肝纤维化过程中,激活的肝星状细胞(HSC)和库否细胞(KCs),在肝纤维化过程中,发挥重要的作用。本研究探究了肝纤维化的分子机制,分析了鞘氨醇激酶-1(SphK-1)在肝纤维化过程中发挥的作用。

研究结果:相比正常的人类肝组织,肝纤维化的肝组织中,SphK1的表达和活性显著增加。SphK1与HSC/KC激活标志物—肌间线蛋白、a-平滑肌蛋白(alpha-SMA)以及F4/80共同在肝纤维化肝组织中表达。在CCl4或胆管结扎(BDL)诱导的小鼠肝纤维化模型中,SphK1(SphK1(-/-)缺乏导致肝损伤显著改善,包括转氨酶活性、组织学、胶原沉积、a-平滑肌蛋白和炎症等。采用SphK1抑制剂-5C,显著地阻止了肝损伤和肝纤维化程度。在细胞水平,抑制SphK1显著地阻止了HSCs和KCs的迁移和激活。此外,敲除KCs中的SphK1基因,CCL2分泌减少;敲除HSCs中的SphK1基因,CCR2表达减少(CCR2 为CCL2受体)。相比野生型小鼠,在SphK1(-/-) 小鼠, CCL2 表达减少;然而,SphK1(-/-) 小鼠中microRNA-19b-3p表达增多。进一步,在HSCs中,microRNA-19b-3p下调了CCR2的表达。利用骨髓移植(BMT)的动物实验结果,进一步确认了SphK1在肝纤维化方面的功能效应。

研究结论:在肝纤维化中,在激活KCs和HSCs中,SphK1具有独特的作用。从机制上说,在KCs中,SphK1减少 CCL2的分泌;在HSCs,SphK1通过下调 miR-19b-3p的表达,促进CCR2的表达。

原始出处

Lan T, Li C, Yang G, et al. Sphingosine kinase 1 promotes liver fibrosis by preventing miR-19b-3p-mediated inhibition of CCR2. Hepatology, 2018, 68(3), 1070-1086.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1974310, encodeId=506c19e4310f5, content=<a href='/topic/show?id=b66499992af' target=_blank style='color:#2F92EE;'>#鞘氨醇激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99992, encryptionId=b66499992af, topicName=鞘氨醇激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jan 15 15:25:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808225, encodeId=ea6a1808225c8, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Apr 13 09:25:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977731, encodeId=94d019e7731c0, content=<a href='/topic/show?id=4b7d4230bd' target=_blank style='color:#2F92EE;'>#CCR2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4230, encryptionId=4b7d4230bd, topicName=CCR2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 18 14:25:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427249, encodeId=ede8142e2496f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Sep 29 12:25:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496032, encodeId=afb014960320c, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Sat Sep 29 12:25:00 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1974310, encodeId=506c19e4310f5, content=<a href='/topic/show?id=b66499992af' target=_blank style='color:#2F92EE;'>#鞘氨醇激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99992, encryptionId=b66499992af, topicName=鞘氨醇激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jan 15 15:25:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808225, encodeId=ea6a1808225c8, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Apr 13 09:25:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977731, encodeId=94d019e7731c0, content=<a href='/topic/show?id=4b7d4230bd' target=_blank style='color:#2F92EE;'>#CCR2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4230, encryptionId=4b7d4230bd, topicName=CCR2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 18 14:25:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427249, encodeId=ede8142e2496f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Sep 29 12:25:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496032, encodeId=afb014960320c, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Sat Sep 29 12:25:00 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1974310, encodeId=506c19e4310f5, content=<a href='/topic/show?id=b66499992af' target=_blank style='color:#2F92EE;'>#鞘氨醇激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99992, encryptionId=b66499992af, topicName=鞘氨醇激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jan 15 15:25:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808225, encodeId=ea6a1808225c8, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Apr 13 09:25:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977731, encodeId=94d019e7731c0, content=<a href='/topic/show?id=4b7d4230bd' target=_blank style='color:#2F92EE;'>#CCR2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4230, encryptionId=4b7d4230bd, topicName=CCR2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 18 14:25:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427249, encodeId=ede8142e2496f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Sep 29 12:25:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496032, encodeId=afb014960320c, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Sat Sep 29 12:25:00 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2018-12-18 meichuangyi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1974310, encodeId=506c19e4310f5, content=<a href='/topic/show?id=b66499992af' target=_blank style='color:#2F92EE;'>#鞘氨醇激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99992, encryptionId=b66499992af, topicName=鞘氨醇激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jan 15 15:25:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808225, encodeId=ea6a1808225c8, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Apr 13 09:25:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977731, encodeId=94d019e7731c0, content=<a href='/topic/show?id=4b7d4230bd' target=_blank style='color:#2F92EE;'>#CCR2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4230, encryptionId=4b7d4230bd, topicName=CCR2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 18 14:25:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427249, encodeId=ede8142e2496f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Sep 29 12:25:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496032, encodeId=afb014960320c, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Sat Sep 29 12:25:00 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2018-09-29 gwc384
  5. [GetPortalCommentsPageByObjectIdResponse(id=1974310, encodeId=506c19e4310f5, content=<a href='/topic/show?id=b66499992af' target=_blank style='color:#2F92EE;'>#鞘氨醇激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99992, encryptionId=b66499992af, topicName=鞘氨醇激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jan 15 15:25:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808225, encodeId=ea6a1808225c8, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Apr 13 09:25:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977731, encodeId=94d019e7731c0, content=<a href='/topic/show?id=4b7d4230bd' target=_blank style='color:#2F92EE;'>#CCR2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4230, encryptionId=4b7d4230bd, topicName=CCR2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 18 14:25:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427249, encodeId=ede8142e2496f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Sep 29 12:25:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496032, encodeId=afb014960320c, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Sat Sep 29 12:25:00 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2018-09-29 redcrab

相关资讯

Hepatology:鞘氨醇激酶1通过下调miR-19b-3p的表达来增加CCR2的表达,进而促进肝纤维化

在肝纤维化过程中,SphK1对KCs和HSCs的激活具有明显不同的作用。在机制上,在KCs中SphK1介导CCL2的分泌;在HSC中,SphK1通过下调miR-19b-3p的表达来增加CCR2的表达。

Baidu
map
Baidu
map
Baidu
map